| abstract |
The present invention provides a method of treating or inhibiting a medical disorder selected from a compound of formula I, an N-oxide thereof, a tautomer thereof, a prodrug thereof and pharmaceutically acceptable salts thereof, and neurological disorders and psychotic disorders , Alleviating the symptoms associated with the disorders, and reducing the risk of the disorders. Formula I In the formula (I) The variables X, Y, Q 1 and Q 2 have the following meanings, X is CR 3 Or N; Q 1 is S or O, Q 2 is CR 4 or N and Q 2 is connected to X as a double bond, while Q 1 is connected to X as a single bond; or Q 2 is S or O, and Q 1 is CR 4 Or N Q 1 is connected to X by a double bond, while Q 2 is connected to X by a single bond; Y is CR 5 Or N; In the above formula (I), the variables R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the claims. The compounds of formula (I), their N-oxides, their tautomers, their prodrugs and their pharmaceutically acceptable salts are inhibitors of phosphodiesterase type 10A. |